These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 8879475)

  • 1. Serum cholesterol and treatment-resistance in schizophrenia.
    Boston PF; Dursun SM; Zafar R; Reveley MA
    Biol Psychiatry; 1996 Sep; 40(6):542-3. PubMed ID: 8879475
    [No Abstract]   [Full Text] [Related]  

  • 2. LDL cholesterol estimation using the Anandaraja's and Friedewald's formulas in schizophrenic patients treated with antipsychotic drugs.
    Paz E; Hermida J; Bouzas L; Brenlla J; Tutor JC
    Clin Biochem; 2008 Aug; 41(12):1002-7. PubMed ID: 18474233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study.
    Dursun SM; Szemis A; Andrews H; Reveley MA
    J Psychiatry Neurosci; 1999 Nov; 24(5):453-5. PubMed ID: 10586536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The lipid profiles in Japanese patients with schizophrenia treated with antipsychotic agents.
    Watanabe J; Suzuki Y; Sugai T; Fukui N; Ono S; Tsuneyama N; Saito M; Someya T
    Gen Hosp Psychiatry; 2012; 34(5):525-8. PubMed ID: 22591814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nifedipine in neuroleptic-refractory schizophrenia.
    Kramer MS; DeMaria P; Morrow R; DiJohnson C; Sheves P
    J Clin Psychopharmacol; 1987 Jun; 7(3):195-6. PubMed ID: 2885346
    [No Abstract]   [Full Text] [Related]  

  • 6. A preliminary investigation of alpha-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia.
    Kim E; Park DW; Choi SH; Kim JJ; Cho HS
    J Clin Psychopharmacol; 2008 Apr; 28(2):138-46. PubMed ID: 18344723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia.
    Murashita M; Inoue T; Kusumi I; Nakagawa S; Itoh K; Tanaka T; Izumi T; Hosoda H; Kangawa K; Koyama T
    Psychiatry Clin Neurosci; 2007 Feb; 61(1):54-8. PubMed ID: 17239039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic profiling identifies TC and LDL as potential serum biomarkers for depressive symptoms in schizophrenia.
    Fang X; Chen L; Wang D; Yu L; Wang Y; Chen Y; Ren J; Tang W; Zhang C
    Psychiatry Res; 2019 Nov; 281():112522. PubMed ID: 31521045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of phenothiazine drugs on serum levels of apolipoproteins and lipoproteins in schizophrenic subjects.
    Wen F; Tan J
    Acta Pharmacol Sin; 2003 Oct; 24(10):1001-5. PubMed ID: 14531942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of treatment refractory schizophrenia.
    Morrison DP
    Br J Psychiatry Suppl; 1996 Dec; (31):15-20. PubMed ID: 8968651
    [No Abstract]   [Full Text] [Related]  

  • 11. Proceedings: Butaclamol in the treatment of schizophrenia--a comparison of two treatment methods.
    Imaz F; Ban TA; Lehmann HE
    Psychopharmacol Bull; 1976 Jan; 12(1):31-4. PubMed ID: 1826
    [No Abstract]   [Full Text] [Related]  

  • 12. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment.
    Pirildar S; Gönül AS; Taneli F; Akdeniz F
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jul; 28(4):709-13. PubMed ID: 15276697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of risperidone on lipid profile.
    Khalili H; Dashti-Khavidaki S; Okhovatpour H; Ghaeli P
    Ann Pharmacother; 2007 May; 41(5):899-900. PubMed ID: 17426072
    [No Abstract]   [Full Text] [Related]  

  • 14. Factors which can make patients difficult to treat.
    Kane JM
    Br J Psychiatry Suppl; 1996 Dec; (31):10-4. PubMed ID: 8968650
    [No Abstract]   [Full Text] [Related]  

  • 15. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics.
    Tan YL; Zhou DF; Cao LY; Zou YZ; Zhang XY
    Neurosci Lett; 2005 Jul 1-8; 382(1-2):27-32. PubMed ID: 15911116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine.
    Friedman J; Ault K; Powchik P
    Biol Psychiatry; 1997 Sep; 42(6):522-3. PubMed ID: 9285089
    [No Abstract]   [Full Text] [Related]  

  • 17. Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment.
    Lee AH; Lange C; Ricken R; Hellweg R; Lang UE
    J Clin Psychopharmacol; 2011 Jun; 31(3):334-6. PubMed ID: 21508862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
    Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
    Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quetiapine for elderly non-responsive schizophrenia patients.
    Mazeh D; Paleacu D; Barak Y
    Psychiatry Res; 2008 Jan; 157(1-3):265-7. PubMed ID: 17928067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose versus low-dose strategies in the treatment of schizophrenia.
    Kane JM; Rifkin A; Woerner M; Reardon G; Kreisman D; Blumenthal R; Borenstein M
    Psychopharmacol Bull; 1985; 21(3):533-7. PubMed ID: 2863848
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.